Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sigma Healthcare Ltd ( (AU:SIG) ) has provided an announcement.
Sigma Healthcare Ltd announced key changes in its executive management team, highlighting a strategic focus on talent development and succession planning. Mark Davis will step down as Group CFO, and Damien Gance will transition from executive duties to a non-executive director role. Mark Conway is appointed Chief Strategy and Business Development Officer, while Mario Tascone becomes Deputy CEO of Retail. These changes are aimed at supporting Sigma’s growth and integration efforts post-merger, reflecting the company’s commitment to strengthening its management team and executing long-term growth plans.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
More about Sigma Healthcare Ltd
Sigma Healthcare Ltd operates in the healthcare industry, focusing on pharmaceutical distribution and retail pharmacy services. The company is known for its significant role in the Chemist Warehouse Group merger and its presence in the Australian market.
Average Trading Volume: 30,949,984
Technical Sentiment Signal: Hold
Current Market Cap: A$33.07B
Learn more about SIG stock on TipRanks’ Stock Analysis page.